Order Article Reprints

Maranto C, Udhane V, Jia J, Verma R, Müller-Newen G, LaViolette PS, Pereckas M, Sabharwal L, Terhune S, Pattabiraman N, et al. Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo. Cancers. 2020; 12(11):3412. https://doi.org/10.3390/cancers12113412

Maranto, Cristina, Vindhya Udhane, Jing Jia, Ranjit Verma, Gerhard Müller-Newen, Peter S. LaViolette, Michael Pereckas, Lavannya Sabharwal, Scott Terhune, Nagarajan Pattabiraman, and et al. 2020. "Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo" Cancers 12, no. 11: 3412. https://doi.org/10.3390/cancers12113412

Maranto, C., Udhane, V., Jia, J., Verma, R., Müller-Newen, G., LaViolette, P. S., Pereckas, M., Sabharwal, L., Terhune, S., Pattabiraman, N., Njar, V. C. O., Imig, J. D., Wang, L., & Nevalainen, M. T. (2020). Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo. Cancers, 12(11), 3412. https://doi.org/10.3390/cancers12113412